90841-55-7

Usage

Uses

Used in Organic Chemistry:
Benzyl 3-bromopropanoate serves as a reagent in various organic chemistry reactions, facilitating the formation of esters and the bromination process of organic compounds. Its unique structure allows for versatile applications in the synthesis of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, benzyl 3-bromopropanoate is utilized in the synthesis of a range of medicinal compounds. Its ability to participate in key organic reactions makes it a valuable intermediate in the development of new drugs.
Used in Industrial Chemical Synthesis:
Beyond pharmaceuticals, benzyl 3-bromopropanoate is also employed in the production of various industrial chemicals. Its versatility in organic reactions contributes to the creation of a wide array of chemical products used in different sectors.

Upstream product

• 15486-96-1 3-Bromopropionyl chloride 
• 100-51-6 benzyl alcohol 
• 2495-35-4 benzylacrylate 
• 590-92-1 3-Bromopropionic acid 

Downstream Products

• 19186-08-4 3-carboxymethylsulfanyl-propionic acid benzyl ester 
• 93415-08-8 Benzyl 3-iodopropanoate 
• 2495-35-4 benzylacrylate 
• 92912-31-7 tribenzyl 1-benzyl-4-benzyloxycarbonyl-3,6-dioxo-2,2,4-piperidinetripropionate 
• 130245-39-5 2-(1-tert-Butoxycarbonyl-1H-indol-3-ylmethyl)-2-isocyano-pentanedioic acid 5-benzyl ester 1-methyl ester 
• 192760-18-2 benzyl 3-(N'-t-butyloxycarbonylhydrazino)propionate 
• 212519-99-8 4-Acetylamino-4-(diphenoxy-phosphoryl)-butyric acid benzyl ester 
• 1422516-68-4 Boc-Glu(OBzl)-Val-Glu(OBzl)^P(OPh)₂ 
• 1422516-67-3 Boc-Asp(OBzl)-Val-Glu(OBzl)^P(OPh)₂ 
• 1422516-66-2 Boc-Phe-Val-Glu(OBzl)^P(OPh)₂ 
• 1422516-65-1 Boc-Glu(OBzl)-Ala-Glu(OBzl)^P(OPh)₂ 
• 1422516-64-0 Boc-Asp(OBzl)-Ala-Glu(OBzl)^P(OPh)₂ 
• 1422516-82-2 Boc-Phe-Ala-Glu(OBzl)^P(OPh)₂ 
• 1422516-63-9 Boc-Glu(OBzl)-Leu-Glu(OBzl)^P(OPh)₂ 

Relevant academic research and scientific papers

Scalable anti-Markovnikov hydrobromination of aliphatic and aromatic olefins

To improve access to a key synthetic intermediate we targeted a direct hydrobromination-Negishi route. Unsurprisingly, the anti-Markovnikov addition of HBr to estragole in the presence of AIBN proved successful. However, even in the absence of an added initiator, anti-Markovnikov addition was observed. Re-examination of early reports revealed that selective Markovnikov addition, often simply termed "normal" addition, is not always observed with HBr unless air is excluded, leading to the rediscovery of a reproducible and scalable initiator-free protocol.

Phosphonic analogues of glutamic acid as irreversible inhibitors of Staphylococcus aureus endoproteinase GluC: An efficient synthesis and inhibition of the human IgG degradation

Endoproteinase GluC (V8 protease) is one of many virulence factors released by the Staphylococcus aureus species in vivo. The V8 protease is able to hydrolyze some serpins and all classes of mammalian immunoglobulins. The application of specific and potent inhibitors of V8 protease may lead to the development of new antibacterial agents. Herein, we present the synthesis and the inhibitory properties of novel peptidyl derivatives of a phosphonic glutamic acid analogue. One of the compounds Boc-Phe-Leu-GluP(OC 6H4)2 displayed an apparent second-order inhibition rate value of 8540 M-1 s-1. The Boc-Phe-Leu-GluP(OC6H4)2 compound with the highest inhibitory potency showed the ability to prevent V8-mediated human IgG proteolysis in vitro.

MRI CONTRAST AGENTS

The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics.

Derivatisation of an anti-cancer cationic antimicrobial peptide and its complexation to platinum(II)

This work focuses on the cationic antimicrobial peptide (CAP) DP18L with its known propensity to target and selectively kill cancer cells. DP18L was derivatised to dap-DP18L where dap is 2,3-diaminopropionic acid. Dap facilitated binding to PtII/sup

Reporter protein-targeted probes for magnetic resonance imaging

Contrast agents for magnetic resonance imaging are frequently employed as experimental and clinical probes. Drawbacks include low signal sensitivity, fast clearance, and nonspecificity that limit efficacy in experimental imaging. In order to create a bioresponsive MR contrast agent, a series of four Gd(III) complexes targeted to the HaloTag reporter were designed and synthesized. HaloTag is unique among reporter proteins for its specificity, versatility, and the covalent interaction between substrate and protein. In similar systems, these properties produce prolonged in vivo lifetimes and extended imaging opportunities for contrast agents, longer rotational correlation times, and increases in relaxivity (r1) upon binding to the HaloTag protein. In this work we report a new MR contrast probe, 2CHTGd, which forms a covalent bond with its target protein and results in a dramatic increase in sensitivity. A 6-fold increase in r1, from 3.8 to 22 mM-1s-1, is observed upon 2CHTGd binding to the target protein. This probe was designed for use with the HaloTag protein system which allows for a variety of substrates (specific for MRI, florescence, or protein purification applications) to be used with the same reporter.

Peptide and peptide mimetic conjugates with integrin-inhibitor properties

The invention relates to compounds of formula (1) I-Q-X1, wherein B is bioactive cell adhesive mediating molecule. Q is absent or is an inorganic spacer molecule and X1 is an anchor molecule, selected from the group Lys.(CO—CH —(CH2)n—PO3H2)2(I)-Lys[-Lys-(CO—CH2—(CH2)a—PO3H2)2]2(ii) or -Lys-(Lys[-Lys-(CO—CH2—(CH2)n—PO3H2]2 (iii), and n independently represents 0, 1, 2 or 3, wherein a free amino group of group B is linked in peptide form to a free carboxyl group of the spacer molecule Q or of the anchor molecule X1 or a free amino group of the radical Q is linked in peptide form to a free carboxyl group of the radical X1. The invention also relates to the salts thereof. The inventive compounds can be used as integrin inhibitors for the treatment of illnesses, deficiencies, inflammations caused by implants and osteolytic illnesses such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, in addition to the acceleration and strengthening of the integration process of implants or the biocompatible surface in tissue.

Stereoselective synthesis of a set of two functionalized (E)-alkene dipeptide isosteres of L-amino acid-L-Glu and L-amino acid-D-Glu

The stereoselective synthesis of a set of two functionalized (E)-alkene dipeptide isosteres of L-amino acid-L-Glu and L-amino acid-D-Glu was carried out. The treatment of N-arylsulfonyl-γ,δ-cis- or -trans-γ,δ-epimino (E)-α,β-enoates with HCl-1,4-dioxane afforded regio- and stereo-selective ring-opened products. The ring-opening reaction provided a useful method for the stereoselective synthesis of a set of diastereomeric (L-Xaa, L-Glu)-type and (L-Xaa, D-Glu)-type (E)-alkene dipeptide isosteres (EADI) from a single substrate of γ,δ-epimino (E)-α,β-enoate using organozinc-copper reagents.

SUBSTITUTED CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula STR1 wherein each T is a substituent g roup; x is 0, 1, or 2; the group D represents STR2 the subscript "e" is 2 or 3; the group R 14 represents a variety of possible substituent groups of the cycloalkyl ring between D and G; the subscript "k" is 0-2; and the group G represents M, STR3 in which M represents--CO 2 H,--CON(R 11) 2, or--CO 2 R 12 ; and R 13 represents any of the side chains of the 19 noncyclic occurring amino acids. "

Conformational Study of Bridgehead Lactams. Preparation and X-Ray Structural Analysis of 1-Azabicyclononane-2,6-dione

3-(2-carboxyethyl)-4-piperidone (5) prepared, from N-benzyl-4-piperidone and benzyl acrylate (9), was thermally cyclized in the presence of dibutyltin oxide to 1-azabicyclononane-2,6-dione (4), which possesses a bridgehead amide nitrogen.The boat-chair conformation of (4) in the solid state has been characterized by X-ray crystal structure analysis and the bridgehead amide shown to be appreciably distorted from planarity, with N(1) displaced by 0.37 Angstroem from the plane of C(2), C(8), and C(9).Crystallographic data are a=6.214(4), b=6.845(5), c=17.850(8) Angstroem, Z=4, space group P21cn.X-Ray intensity measurements were made on a four-circle diffractometer and least-squares adjustment of the atomic parameters converged at R=0.038 for 1004 reflections.